- Percheron could double if clinical goes well
- But Taylor Collison admits that PER is a speculative investment
- Probiotec meanwhile offers a resilient business model, says Sequoia
Perceheron could double after trial readout at year-endTaylor Collison has slapped an
Outperform rating on
Percheron Therapeutics (ASX
ER), with a
price target of 15c (versus current price of 8c), noting however that it’s a “speculative investment”.
Formerly called
Antisense Therapeutics, Percheron is a $73m market capped biotech developing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc.
Antisense pharmaceuticals are a type of drug that work by targeting specific RNA molecules within cells, with the potential to treat a variety of diseases, including certain types of cancer, genetic disorders, and viral infections.
Taylor believes Percheron is on track for a
Duchenne muscular dystrophy (DMD) topline clinical trial readout around the end of 2024.
The company is currently undergoing a Phase IIa study, treating DMD patients with its flagship drug,
ATL1102.
“The corporate slide deck released last week continued to guide that PER expects to complete recruitment in the Phase IIb trial in the current quarter, but we see a high probability that recruitment will extend into Q2 CY24,” said the note from Taylor.
DMD is a genetic disorder characterised by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood around ages 3 to 5.
So far, the study has shown encouraging improvement in upper limb function of the patients, including PUL 2.0 scores, in marked contrast to the progressive deterioration that is the hallmark of DMD.
The Phase IIb trial will primarily serve as a signal-finding study to determine whether the drug is likely to be an effective treatment for DMD.
“However, if the results are sufficiently positive, they could potentially support an application for marketing approval of ATL1102,” said Taylor Collison.
The Phase IIb trial aims to recruit 45 non-ambulant DMD patients at 16 trial sites in Turkey, Bulgaria, Australia, Serbia and the UK. The majority of trial sites are now open for recruitment, including two sites in Serbia which opened in January.
At the completion of the six-month blinded treatment period, all subjects will have received ATL1102 in an open label treatment period. This open label extension will collect important long term safety and efficacy data.
Percheron is well funded to complete the trial. It had $17.2m cash on 31 December, and received a $1.6m R&D tax incentive payment in February.
“These resources give it a funding runway well beyond the expected release of topline data from the Phase IIb trial,” said Taylor Collison.
double? i would think more than that.
